Boston Scientific Corporation (BSX)
Healthcare · Medical - Devices · Data as of 2026-09-01
Bottom line
BSX is trading at a discount to its history, near its historical support zone, and recent volume shows no clear direction. Historically, this combination has been a favourable starting point for further research. Past patterns are not a guarantee of future results.
Valuation — Trading at a discount to its history (Green)
BSX trades at 19× earnings, below its own 5-year average of 61× and below similar healthcare companies we track (29×, 52 peers). Historically this has been on the cheaper side for the stock. Its free-cash-flow yield is about 5.2%. Its current multiple sits around the 2nd percentile of its own last five years — toward the low end of its own range. Its fundamentals scored 7 of 9 on a standard year-over-year quality checklist — most of the underlying trends improved last fiscal year.
Price zones — Near its historical support zone (Green)
At $48.08, the stock is close to the lower end of its recent range. Over the past year BSX has traded between $42.20 and $109.50; its historical support zone sits near $46.71 and resistance near $67.59. It is above one of its moving averages and below the other — a mixed trend picture.
52-week range $42.20–$109.50 · 50-day average $46.71 · 200-day average $67.59
Money flow — No clear direction (Yellow)
Buying and selling volume in BSX have been fairly balanced recently, with no strong accumulation or distribution pattern. Volume on up days has been about 1.5× volume on down days over the last 30 sessions.
About the company
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns.
一句话结论
BSX 相对自身历史处于折价水平，接近其历史支撑区，近期成交量没有明确方向。从历史来看，这样的组合是一个值得进一步研究的有利起点。过去的形态并不能保证未来的结果。
估值 — 相对自身历史处于折价水平
BSX 目前的市盈率为 19×，低于其自身 5 年平均的 61×，并且低于我们追踪的同类Healthcare公司（29×，52 家）。从历史来看，这属于该股较便宜的一侧。其自由现金流收益率约为 5.2%。它当前的估值倍数大约位于自身过去五年分布的第 2 百分位——处于自身区间的偏低位置。在一套标准的逐年基本面核对清单上，它 9 项中通过了 7 项——上一财年多数底层趋势在改善。
价格区间 — 接近其历史支撑区
目前价格为 $48.08，接近其近期区间的下沿。过去一年 BSX 的价格在 $42.20 到 $109.50 之间波动；其历史支撑区在 $46.71 附近，阻力区在 $67.59 附近。它位于其中一条均线上方、另一条下方——趋势信号并不一致。
资金流向 — 方向不明确
BSX 近期的买卖成交量大致均衡，没有明显的吸筹或派发形态。过去 30 个交易日，上涨日的成交量约为下跌日的 1.5×。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.